ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis
SAN CARLOS, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the outcome of the U.S. Food and Drug Administration (“FDA”) Arthritis Advisory...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Arthritis | Clinical Trials | Food and Drug Administration (FDA) | Pharmaceuticals | Rheumatology | Vasculitis